Navigation Links
Cephalon's EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
Date:1/24/2008

FRAZER, Pa. and MAISONS-ALFORT, France, Jan. 24 /PRNewswire-FirstCall/ -- Cephalon, Inc., (Nasdaq: CEPH) announced today that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion regarding EFFENTORA(TM), the company's fentanyl buccal tablet pain medication. In March 2007, Cephalon submitted the EFFENTORA European new drug application for the treatment of breakthrough pain in adult cancer patients who are already receiving maintenance opioid therapy for chronic cancer pain. The CHMP recommendation for EFFENTORA will now be forwarded to the European Commission for final marketing approval, which typically occurs within 60 to 90 days.

"We believe this product, once approved, will be an exciting addition to our European product portfolio and will provide a tremendous benefit to patients suffering from breakthrough cancer pain," said Alain Aragues, President Cephalon Europe. "Cephalon is committed to bringing innovative medications to the European market and we are delighted to receive this positive opinion for EFFENTORA from the CHMP."

The prevalence of cancer in Europe is estimated at approximately 2.9 million patients according to the most recent report from GLOBOCAN, a worldwide database of cancer statistics. A large majority of these patients will experience breakthrough cancer pain, a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent chronic pain. Patients experience intense transient flares of pain that interrupt, or "break through," their background persistent pain. Breakthrough pain is characterized by its rapid onset, moderate-to-severe intensity and a relatively short duration. In cancer, the onset
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neptune Technologies receives GRAS notification in the United States
2. 012 Smile.Communications Receives License to Provide Endpoint Network Services
3. Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure
4. SDCRM Receives Highest Score in Three of Four Categories from CIRM on Part I of Major Facilities Grant Application
5. Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System
6. Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Genta Receives Notice of Non-Compliance With NASDAQ Rule
9. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
10. Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service
11. EaglePicher Technologies Receives Battery Power Products and Technologys First Annual Innova Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... (PRWEB) September 30, 2014 Proove ... medicine, is excited to announce a new genetic test ... The Proove Pain Perception Test will provide physicians ... and why pain tolerance levels are stratified between individuals. ... identify whether a person has a genetic predisposition that ...
(Date:9/30/2014)... Fla. , Sept. 30, 2014 CORD:USE ... pleased to announce that it has entered into an ... Inc. (Tianhe) which has licensed a series of patented technologies ... cells for possible clinical applications.  Tianhe is performing Phase ... and Spain using Tianhe,s Stem ...
(Date:9/30/2014)... September 30, 2014 OriginOil Inc. (OTC/QB: ... chemical-free process to clean up large quantities of water, ... Riggs Eckelberry reported on the launch of the company's ... site provided by partner STW Resources . , ... barrels per day (bpd) and achieved a 99.8% reduction ...
(Date:9/30/2014)... DEL MAR, Calif. , Sept. 30, 2014 /PRNewswire/ ... devices for women,s health announces its receipt of a ... The FemmyCycle menstrual cup has also received FDA clearance ... Health Canada, and the CE in Europe. This patent is ... design. In conjunction with this issuance, the company is releasing ...
Breaking Biology Technology:Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2The FemmyCycle 2
... Emmy® and Tony® award-winning actress Blythe Danner and Amgen ... Reduce Fractures™, an educational campaign for women with postmenopausal ... Danner was diagnosed with postmenopausal osteoporosis at increased risk ... to educate themselves, take action and speak to their ...
... August 25, 2011 Amsterdam Molecular Therapeutics (Euronext: ... today reported its results for the first half year of ... , Glybera®: , Data showing Glybera produces significant reduction ... Atherosclerosis Society Meeting CHMP does not consider Glybera ...
... Biocept, Inc., a privately-held CLIA-certified laboratory testing company, focused ... (CTCs) in cancer patients, and Clarient, Inc. (a GE ... of a proprietary blood test for CTCs in breast ...  Clarient and Biocept will market and sell Biocept,s new ...
Cached Biology Technology:Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign 2Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign 3Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign 4Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign 5Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign 6Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign 7Amsterdam Molecular Therapeutics Reports Half-Year Results 2011 2Amsterdam Molecular Therapeutics Reports Half-Year Results 2011 3Amsterdam Molecular Therapeutics Reports Half-Year Results 2011 4Amsterdam Molecular Therapeutics Reports Half-Year Results 2011 5Amsterdam Molecular Therapeutics Reports Half-Year Results 2011 6Amsterdam Molecular Therapeutics Reports Half-Year Results 2011 7Amsterdam Molecular Therapeutics Reports Half-Year Results 2011 8Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 Status in Breast Cancer Patients 2Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 Status in Breast Cancer Patients 3Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 Status in Breast Cancer Patients 4
(Date:9/30/2014)... that a new class of chemical compounds makes ... have also pinpointed the relevant target enzyme, thus ... , Researchers led by LMU,s Professor Angelika Vollmar ... Mnchen have identified a class of chemicals that ... against malignant tumors. The compound is itself non-toxic, ...
(Date:9/30/2014)... of perilous threats in today,s ocean. From overfishing ... fragile coral ecosystems are disappearing at unprecedented rates ... of corals surrounding the island of Moorea in ... tropical environment: coral guard-crabs. New research from the ... scientist Seabird McKeon and the museum,s predoctoral fellow ...
(Date:9/29/2014)... DC September 29, 2014 -- Plants have ... bacteria help the pants extract nutrients and defend ... pathogens from contaminating fruits and vegetables. Now, scientist ... bacteria inside of seeds; thus ensuring that sprouting ... from the University of Notre Dame, presented their ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Smithsonian scientists discover coral's best defender against an army of sea stars 2Plants prepackage beneficial microbes in their seeds 2
... the past three decades, saturated fat has been considered a major ... persists in recommending reduced consumption of this macronutrient. However, new ... impact on CVD risk -- causing many to rethink the "saturated ... articles published in the October issue of Lipids ...
... New York, 1 October, 2010 A special article ... the recent Report of the 2010 Dietary Guidelines Advisory Committee ... to conform to the standards of evidence-based medicine, despite its ... The authors call the DGAC to task for failing to ...
... protein, STIM1, known to activate store-operated calcium channels has ... to researchers at Temple University. The researchers published ... Orai and Cav1.2 Channels, in the Oct. 1 issue ... Calcium, not just important for bones and teeth, is ...
Cached Biology News:Think saturated fat contributes to heart disease? Think again 2Think saturated fat contributes to heart disease? Think again 3Proposed dietary guidelines for Americans sharply debated 2Protein provides link between calcium signaling in excitable and non-excitable cells 2
Mouse monoclonal antibody raised against a partial recombinant EOMES. NCBI Entrez Gene ID = EOMES...
...
Rabbit polyclonal to MCP2 ( Abpromise for all tested applications). entrezGeneID: 6355 SwissProtID: P49873...
Mouse monoclonal antibody raised against a partial recombinant AATK. NCBI Entrez Gene ID = AATK...
Biology Products: